CAR-T-cells specific for CD19 have demonstrated complete and durable remissions in 70–90% of Acute Lymphoblastic Leukemia (ALL) patients that have failed multiple lines of prior therapy [2]. Here, CD19 is linked to acute lymphoblastic leukemia.